Gain Therapeutics, Inc. (GANX): Price and Financial Metrics

Gain Therapeutics, Inc. (GANX): $1.21

0.01 (-0.82%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add GANX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#167 of 340

in industry

GANX Price/Volume Stats

Current price $1.21 52-week high $5.33
Prev. close $1.22 52-week low $1.11
Day low $1.21 Volume 82,700
Day high $1.23 Avg. volume 209,096
50-day MA $1.86 Dividend yield N/A
200-day MA $3.03 Market Cap 21.84M

GANX Stock Price Chart Interactive Chart >


Gain Therapeutics, Inc. (GANX) Company Bio


Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.


GANX Latest News Stream


Event/Time News Detail
Loading, please wait...

GANX Latest Social Stream


Loading social stream, please wait...

View Full GANX Social Stream

Latest GANX News From Around the Web

Below are the latest news stories about GAIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GANX as an investment opportunity.

Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics, Inc. (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Yahoo | December 14, 2023

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat, hosted by FORCE Family Office, with John Vandermosten, CFA, Senior Analyst for Zacks Small-Cap Research taking place Tuesday, December 5, 2023. Fireside Chat

Yahoo | December 4, 2023

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Compounds significantly restored β-Gal function and reduced intracellular toxic substrates in model of GM1 gangliosidosis Results published in PLOS ONE in collaboration with Institute for Research in Biomedicine BETHESDA, Md., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the publication of preclinical data identi

Yahoo | December 1, 2023

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will participate on a panel during the AI Driven Drug Discovery Summit taking place at the Sheraton Boston Hotel, in Boston, Massachusetts December 5-6, 2023. AI Driven Drug Discovery SummitDate: Wednesday, D

Yahoo | November 29, 2023

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

BETHESDA, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the closing of an underwritten public offering of 2,545,000 shares of its common stock and warrants to purchase up to an aggregate of 1,272,500 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant, including 331,956 shares of common stock and warrants to purchase 165,978 shares of common stock issued pursuant to t

Yahoo | November 24, 2023

Read More 'GANX' Stories Here

GANX Price Returns

1-mo -6.92%
3-mo -61.95%
6-mo -64.62%
1-year -71.86%
3-year -86.79%
5-year N/A
YTD -62.94%
2023 4.31%
2022 -42.36%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!